<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="10.1212/NXI.0000000000000781 : 131360294182185: Article Guillain-BarrÃ© syndrome: The first documented COVID-19â€&quot;triggered" exact="autoimmune" post="neurologic diseaseMore to come with myositis in the offing"/>
 <result pre="The first documented COVID-19â€&quot;triggered autoimmune neurologic diseaseMore to come with" exact="myositis" post="in the offing DalakasMarinos C.MD[], Correspondence Dr. Dalakas marinos.dalakas@jefferson.edu"/>
 <result pre="funded by the author. collection: 2020-9epub: 2020-6-6pmc-release: 2020-6-675e781received: 2020-5-01accepted: 2020-5-04(C)" exact="American" post="Academy of Neurology, 2020This is an open access article"/>
 <result pre="Abstract Objective To present the COVID-19â€&quot;associated GBS, the prototypic viral-triggered" exact="autoimmune disease," post="in the context of other emerging COVID-19â€&quot;triggered autoimmunities, and"/>
 <result pre="response to therapies and cross-reactivity of COVID spike proteins with" exact="nerve" post="glycolipids. Emerging cases of COVID-19â€&quot;triggered autoimmune necrotizing myositis (NAM)"/>
 <result pre="COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19â€&quot;triggered" exact="autoimmune" post="necrotizing myositis (NAM) and encephalopathies are also reviewed in"/>
 <result pre="proteins with nerve glycolipids. Emerging cases of COVID-19â€&quot;triggered autoimmune necrotizing" exact="myositis" post="(NAM) and encephalopathies are also reviewed in the context"/>
 <result pre="(NAM) and encephalopathies are also reviewed in the context of" exact="viral" post="invasion, autoimmunity and ongoing immunotherapies. Results Collective data indicate"/>
 <result pre="indicate that in this pandemic any patient presenting with an" exact="acute" post="paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms,"/>
 <result pre="pandemic any patient presenting with an acute paralytic disease-like GBS," exact="encephalomyelitis" post="or myositis-even without systemic symptoms, may represent the first"/>
 <result pre="with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without" exact="systemic" post="symptoms, may represent the first manifestation of COVID-19. Anosmia,"/>
 <result pre="and lymphocytopenia are red flags enhancing early diagnostic suspicion. In" exact="Miller-Fisher" post="Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were"/>
 <result pre="antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19â€&quot;bearing gangliosides and" exact="peripheral" post="nerve glycolipids was addressed. Elevated Creatine Kinase (&amp;gt;10,000) is"/>
 <result pre="typically cause ataxic neuropathy, cross-reactivity between COVID-19â€&quot;bearing gangliosides and peripheral" exact="nerve" post="glycolipids was addressed. Elevated Creatine Kinase (&amp;gt;10,000) is reported"/>
 <result pre="cross-reactivity between COVID-19â€&quot;bearing gangliosides and peripheral nerve glycolipids was addressed." exact="Elevated" post="Creatine Kinase (&amp;gt;10,000) is reported in 10% of COVID-19â€&quot;infected"/>
 <result pre="10% of COVID-19â€&quot;infected patients; two such patients presented with painful" exact="muscle" post="weakness responding to IVIg indicating that COVID-19â€&quot;triggered NAM is"/>
 <result pre="indicating that COVID-19â€&quot;triggered NAM is an overlooked entity. Cases of" exact="acute" post="necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and"/>
 <result pre="brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced" exact="demyelinating" post="lesions are now emerging with the need to explore"/>
 <result pre="need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of" exact="chronic" post="immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents"/>
 <result pre="were addressed; the role of complement in innate immunity to" exact="viral" post="responses and anti-complement therapeutics (i.e. eculizumab) were reviewed. Conclusions"/>
 <result pre="indicate that COVID-19 can trigger not only GBS but other" exact="autoimmune" post="neurological diseases necessitating vigilance for early diagnosis and therapy"/>
 <result pre="with pre-existing autoimmunity, there is no evidence that patients with" exact="autoimmune" post="neurological diseases stable on common immunotherapies are facing increased"/>
 <result pre="there is no evidence that patients with autoimmune neurological diseases" exact="stable" post="on common immunotherapies are facing increased risks of infection."/>
 <result pre="Guillain-BarrÃ© syndromes (GBSs) comprise a spectrum of polyneuropathies characterized by" exact="acute" post="(within 1â€&quot;4 weeks) ascending motor weakness, mild or moderate"/>
 <result pre="ascending motor weakness, mild or moderate sensory abnormalities, occasional cranial" exact="nerve" post="involvement, and muscle or radicular pain. According to the"/>
 <result pre="mild or moderate sensory abnormalities, occasional cranial nerve involvement, and" exact="muscle" post="or radicular pain. According to the degree of involvement"/>
 <result pre="the motor or sensory nerves, myelin sheath, axon, or cranial" exact="nerve" post="predominance, the most common subtypes are the acute inflammatory"/>
 <result pre="or cranial nerve predominance, the most common subtypes are the" exact="acute" post="inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN),"/>
 <result pre="nerve predominance, the most common subtypes are the acute inflammatory" exact="demyelinating" post="polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and the"/>
 <result pre="predominance, the most common subtypes are the acute inflammatory demyelinating" exact="polyneuropathy" post="(AIDP), acute motor axonal neuropathy (AMAN), and the Miller"/>
 <result pre="most common subtypes are the acute inflammatory demyelinating polyneuropathy (AIDP)," exact="acute" post="motor axonal neuropathy (AMAN), and the Miller Fisher syndrome"/>
 <result pre="subtypes are the acute inflammatory demyelinating polyneuropathy (AIDP), acute motor" exact="axonal neuropathy" post="(AMAN), and the Miller Fisher syndrome (MFS) characterized by"/>
 <result pre="are the acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal" exact="neuropathy" post="(AMAN), and the Miller Fisher syndrome (MFS) characterized by"/>
 <result pre="demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and the" exact="Miller Fisher syndrome" post="(MFS) characterized by acute ophthalmoplegia, gait ataxia, and areflexia.1"/>
 <result pre="polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and the Miller" exact="Fisher syndrome" post="(MFS) characterized by acute ophthalmoplegia, gait ataxia, and areflexia.1"/>
 <result pre="(AIDP), acute motor axonal neuropathy (AMAN), and the Miller Fisher" exact="syndrome" post="(MFS) characterized by acute ophthalmoplegia, gait ataxia, and areflexia.1"/>
 <result pre="neuropathy (AMAN), and the Miller Fisher syndrome (MFS) characterized by" exact="acute" post="ophthalmoplegia, gait ataxia, and areflexia.1 GBS is one of"/>
 <result pre="ataxia, and areflexia.1 GBS is one of the prototypic viral-triggered" exact="autoimmune" post="neurologic diseases as approximately 70% of the patients have"/>
 <result pre="of the patients have a preceding by 1â€&quot;3 weeks, flu-like," exact="viral" post="illness.1â€&quot;3 Among the infectious agents associated with triggering sporadic"/>
 <result pre="a preceding by 1â€&quot;3 weeks, flu-like, viral illness.1â€&quot;3 Among the" exact="infectious" post="agents associated with triggering sporadic GBS are viruses, including"/>
 <result pre="sporadic GBS are viruses, including influenza, enteroviruses, cytomegalovirus, Epsteinâ€&quot;Barr virus," exact="herpes" post="simplex virus, hepatitis, or HIV, and bacteria, such as"/>
 <result pre="and Haemophilus influenzae.1 GBS outbreaks have been also associated with" exact="viral" post="epidemics or pandemics, including H1N1, swine flu A/New Jersey"/>
 <result pre="been also associated with viral epidemics or pandemics, including H1N1," exact="swine flu" post="A/New Jersey influenza strain, arthropod-borne flaviviruses, such as the"/>
 <result pre="chikungunya, or Zika, and with coronaviruses, including the Middle East" exact="respiratory" post="syndrome (MERS)-CoV and SARS-CoV.1â€&quot;3 We are now more than"/>
 <result pre="or Zika, and with coronaviruses, including the Middle East respiratory" exact="syndrome" post="(MERS)-CoV and SARS-CoV.1â€&quot;3 We are now more than 4"/>
 <result pre="months into the peak of the COVID-19 pandemic with &amp;gt;5,000,000" exact="infections" post="and &amp;gt;330,000 deaths steadily increasingly worldwide, and although various"/>
 <result pre="infections and &amp;gt;330,000 deaths steadily increasingly worldwide, and although various" exact="respiratory" post="and cardiac complications have been reported, we have not"/>
 <result pre="seen COVID-19â€&quot;related neuroinflammatory or neuroautoimmune diseases as with the other" exact="viral" post="outbreaks, including with coronaviruses MERS-CoV and SARS-CoV, which have"/>
 <result pre="including with coronaviruses MERS-CoV and SARS-CoV, which have 75â€&quot;80% identical" exact="viral" post="genome sequence with COVID-19.4 Whether this is due to"/>
 <result pre="sequence with COVID-19.4 Whether this is due to COVID-19â€&quot;inducing severe" exact="respiratory" post="compromise soon after the median 4-day incubation period5 and"/>
 <result pre="In the most up-to-date large published series, apart from multifactorial" exact="acute" post="cerebrovascular events in 5.7% of patients, the main COVID-19â€&quot;related"/>
 <result pre="kinase (CK) levels, with myalgia (in 19.3%) indicating potential CNS," exact="peripheral" post="nervous system, and myopathic manifestations.6 Things are however rapidly"/>
 <result pre="with at least 11 cases of GBS, the prototypic viral-triggered" exact="autoimmune" post="neurologic disease, observed in the 4 main COVID-19 hotspots,"/>
 <result pre="at least 11 cases of GBS, the prototypic viral-triggered autoimmune" exact="neurologic disease," post="observed in the 4 main COVID-19 hotspots, Wuhan, Italy,"/>
 <result pre="4 days after returning to Shanghai from Wuhan presented with" exact="acute" post="lower extremity weakness and areflexia that progressed over 3"/>
 <result pre="days after returning to Shanghai from Wuhan presented with acute" exact="lower" post="extremity weakness and areflexia that progressed over 3 days"/>
 <result pre="that progressed over 3 days to the arms without any" exact="systemic" post="symptoms.7 When first seen, GBS was suspected and confirmed"/>
 <result pre="and confirmed by elevated CSF protein and electromyographic features of" exact="demyelinating" post="neuropathy. Her laboratory test results were normal, except of"/>
 <result pre="immunoglobulin (IVIg) but 4 days later developed fever, cough, and" exact="pneumonia" post="and tested COVID-19 positive. After 3 weeks, her strength"/>
 <result pre="patients with GBS,8 1 in this issue.9 All presented with" exact="subacute" post="onset of upper and lower extremity weakness, distal paresthesias,"/>
 <result pre="1 in this issue.9 All presented with subacute onset of" exact="upper" post="and lower extremity weakness, distal paresthesias, and sensory deficits"/>
 <result pre="this issue.9 All presented with subacute onset of upper and" exact="lower" post="extremity weakness, distal paresthesias, and sensory deficits 3â€&quot;10 days"/>
 <result pre="concentration but was negative for COVID-19. Electrophysiology was consistent with" exact="demyelinating" post="or axonal GBS. MRI showed enhancement of the caudal"/>
 <result pre="was negative for COVID-19. Electrophysiology was consistent with demyelinating or" exact="axonal" post="GBS. MRI showed enhancement of the caudal nerve roots"/>
 <result pre="demyelinating or axonal GBS. MRI showed enhancement of the caudal" exact="nerve" post="roots or facial nerve. Symptoms rapidly progressed to tetraplegia"/>
 <result pre="caudal nerve roots or facial nerve. Symptoms rapidly progressed to" exact="tetraplegia" post="requiring mechanical ventilation. Antiganglioside antibodies in 3/6 tested patients"/>
 <result pre="or polyneuritis cranialis.10 The patient with MFS presented with oculomotor" exact="nerve" post="palsies, diplopia, perioral paresthesias, areflexia, ataxia, and elevated CSF"/>
 <result pre="and elevated CSF protein concentration and the other with diplopia," exact="bilateral" post="abducens nerve palsy, and anosmia. Both had lymphopenia and"/>
 <result pre="elevated CSF protein concentration and the other with diplopia, bilateral" exact="abducens nerve palsy," post="and anosmia. Both had lymphopenia and tested positive for"/>
 <result pre="CSF protein concentration and the other with diplopia, bilateral abducens" exact="nerve" post="palsy, and anosmia. Both had lymphopenia and tested positive"/>
 <result pre="with diplopia, bilateral abducens nerve palsy, and anosmia. Both had" exact="lymphopenia" post="and tested positive for COVID-19; their SCF was COVID-19"/>
 <result pre="IVIg. In both, the neurologic features completely resolved, except for" exact="residual" post="anosmia and ageusia. Last, 2 cases from France, a"/>
 <result pre="a 43-year-old man and a 70-year-old woman, also presented with" exact="acute" post="anosmia, followed by rapidly progressive weakness, paresthesias, ataxia, areflexia,"/>
 <result pre="CSF protein concentration but negative for COVID-19, typical features of" exact="acute" post="demyelinating neuropathy by electrophysiology, and clinical improvement after IVIg.11"/>
 <result pre="protein concentration but negative for COVID-19, typical features of acute" exact="demyelinating" post="neuropathy by electrophysiology, and clinical improvement after IVIg.11 GBS"/>
 <result pre="concentration but negative for COVID-19, typical features of acute demyelinating" exact="neuropathy" post="by electrophysiology, and clinical improvement after IVIg.11 GBS in"/>
 <result pre="GBS in the COVID-19 pandemic These early GBS cases, despite" exact="incomplete" post="immunologic workup considering the enormous difficulties in highly stressed"/>
 <result pre="what to expect in the months ahead regarding the common" exact="acute" post="autoimmune neurologic conditions, such as GBS, polyneuritis cranialis, encephalitis,"/>
 <result pre="to expect in the months ahead regarding the common acute" exact="autoimmune" post="neurologic conditions, such as GBS, polyneuritis cranialis, encephalitis, encephalomyelitis,"/>
 <result pre="now be aware that a patient who presents with an" exact="acute" post="paralytic diseaseâ€&quot;like GBS, encephalomyelitis, or myositisâ€&quot;even without fever, dyspnea,"/>
 <result pre="diseaseâ€&quot;like GBS, encephalomyelitis, or myositisâ€&quot;even without fever, dyspnea, or any" exact="systemic" post="symptoms, may represent the first manifestation of COVID-19. This"/>
 <result pre="red flags in suspecting COVID-19 in otherwise asymptomatic patients with" exact="acute" post="neurologic events. They further confirm what we had feared"/>
 <result pre="events. They further confirm what we had feared from other" exact="viral" post="pandemics that COVID-19 can trigger neurologic autoimmunity; in contrast"/>
 <result pre="of suspicion as a potential hidden trigger to prevent inadvertent" exact="viral" post="transmission to health care personnel and patient relatives, as"/>
 <result pre="unit (ICU) settings helps to distinguish GBS from critical illness" exact="neuropathy" post="that usually appears later in the course of very"/>
 <result pre="very sick ICU patients. Significance of anosmia/ageusia and other cranial" exact="nerve" post="palsies The early manifestation of anosmia and ageusia not"/>
 <result pre="reporting sudden loss of smell and taste early in the" exact="infection" post="in up to 60% of COVID-19 carriers5,6,12 is highly"/>
 <result pre="carriers5,6,12 is highly informative about COVID-19 neurovirulence or even possible" exact="viral" post="entry into the brain. In contrast to commonly reversible"/>
 <result pre="In contrast to commonly reversible anosmia when the non-neural olfactory" exact="epithelial" post="cells are virally infected, the often persistent anosmia/ageusia after"/>
 <result pre="coronaviruses similar to COVID-19, are neurovirulent and can enter the" exact="brain" post="via olfactory nerves.13 In mice, after oronasal infection with"/>
 <result pre="enter the brain via olfactory nerves.13 In mice, after oronasal" exact="infection" post="with SARS-CoV, the virus not only infects epithelial cells"/>
 <result pre="after oronasal infection with SARS-CoV, the virus not only infects" exact="epithelial" post="cells of the respiratory tract but also the olfactory"/>
 <result pre="SARS-CoV, the virus not only infects epithelial cells of the" exact="respiratory" post="tract but also the olfactory receptor neurons in the"/>
 <result pre="and brainstem.13 These viruses can also enter the CNS via" exact="retrograde" post="axonal transport through other cranial nerves, such as trigeminal,"/>
 <result pre="brainstem.13 These viruses can also enter the CNS via retrograde" exact="axonal" post="transport through other cranial nerves, such as trigeminal, which"/>
 <result pre="through other cranial nerves, such as trigeminal, which possesses nociceptive" exact="neuronal" post="receptors in the nasal cavity, the sensory fibers of"/>
 <result pre="nasal cavity, the sensory fibers of the glossopharyngeal, and via" exact="peripheral" post="nerves.13 The present GBS series, where oculomotor, trigeminal, and"/>
 <result pre="with neurologic signs related to multiple cranial nerves, brainstem, and" exact="peripheral" post="nerves with MRI enhancement in nerves and meninges. Autoimmunity"/>
 <result pre="COVID-19â€&quot;GBS: significance of sialic acids present in the coronaviruses and" exact="peripheral" post="nerve myelin In 7/11 tested patients with COVID-19â€&quot;GBS, the"/>
 <result pre="significance of sialic acids present in the coronaviruses and peripheral" exact="nerve" post="myelin In 7/11 tested patients with COVID-19â€&quot;GBS, the virus"/>
 <result pre="was not detected in the CSF, implying no direct root" exact="infection" post="or intrathecal viral replication. The improvement of several patients"/>
 <result pre="in the CSF, implying no direct root infection or intrathecal" exact="viral" post="replication. The improvement of several patients with IVIg and"/>
 <result pre="response similar to other postviral-induced GBS cases1â€&quot;3 or other postviral" exact="autoimmune" post="neurologic disorders.14 The reported GD1b ganglioside antibodies, however, although"/>
 <result pre="shown that the attachment of coronaviruses to the surface of" exact="respiratory" post="cells is mediated by the spike (S) viral protein,"/>
 <result pre="surface of respiratory cells is mediated by the spike (S)" exact="viral" post="protein, which binds not only to the angiotensin-converting enzyme"/>
 <result pre="neuropathy.17 Immunization of rabbits with GDlb also causes sensory ataxic" exact="neuropathy" post="mimicking the human disease.18 Of interest, the first described"/>
 <result pre="disease.18 Of interest, the first described patient with sensory ataxic" exact="neuropathy" post="and GDlb antibodies had also ophthalmoplegia,19 as seen in"/>
 <result pre="the COVID-19 spike-bearing gangliosides and signature sugar residues of surface" exact="peripheral" post="nerve glycolipids is a very likely possibility. Such typical"/>
 <result pre="COVID-19 spike-bearing gangliosides and signature sugar residues of surface peripheral" exact="nerve" post="glycolipids is a very likely possibility. Such typical molecular"/>
 <result pre="likely possibility. Such typical molecular mimicry has been shown between" exact="peripheral" post="nerve glycolipids and Campylobacter jejuni or Zika virus that"/>
 <result pre="possibility. Such typical molecular mimicry has been shown between peripheral" exact="nerve" post="glycolipids and Campylobacter jejuni or Zika virus that also"/>
 <result pre="GM1 gangliosides and, in the presence of chloroquine, the SARS-CoV" exact="viral" post="spike cannot bind gangliosides to infect the targeted cells.15"/>
 <result pre="in conjunction with IVIg. What is more to come with" exact="myositis" post="in the offing Among the other potential COVID-19â€&quot;associated autoimmune"/>
 <result pre="with myositis in the offing Among the other potential COVID-19â€&quot;associated" exact="autoimmune diseases," post="the first alarming concern is inflammatory myopathy, especially necrotizing"/>
 <result pre="diseases, the first alarming concern is inflammatory myopathy, especially necrotizing" exact="autoimmune" post="myositis (NAM) because very high CK levels &amp;gt;10,000 with"/>
 <result pre="the first alarming concern is inflammatory myopathy, especially necrotizing autoimmune" exact="myositis" post="(NAM) because very high CK levels &amp;gt;10,000 with myalgia"/>
 <result pre="reported in more than 10% of COVID-19â€&quot;infected patients.6 Although COVID-19â€&quot;associated" exact="myopathy" post="has not yet been studied but only characterized as"/>
 <result pre="has not yet been studied but only characterized as skeletal" exact="muscle" post="injury or rhabdomyolysis,6 2 just published cases suggest an"/>
 <result pre="muscle injury or rhabdomyolysis,6 2 just published cases suggest an" exact="autoimmune" post="COVID-19â€&quot;triggered NAM. One, an 88-year-old man from New York"/>
 <result pre="NAM. One, an 88-year-old man from New York presented with" exact="acute" post="bilateral thigh weakness and inability to get up from"/>
 <result pre="One, an 88-year-old man from New York presented with acute" exact="bilateral" post="thigh weakness and inability to get up from the"/>
 <result pre="to get up from the toilet, without fever or other" exact="systemic" post="symptoms, and very high CK level (13,581 U/L).20 He"/>
 <result pre="Wuhan had a 6-day history of fever, cough, and COVID-19â€&quot;positive" exact="pneumonia" post="with normal strength and CK; 7 days later, although"/>
 <result pre="although systemically had improved, his CRP doubled and developed painful" exact="muscle" post="weakness with very high CK (11,842 U/L).21 He was"/>
 <result pre="improved while became COVID-19 negative. Myopathic symptoms in a severe" exact="systemic" post="viral disease are multifactorial, but an acute onset of"/>
 <result pre="while became COVID-19 negative. Myopathic symptoms in a severe systemic" exact="viral" post="disease are multifactorial, but an acute onset of severe"/>
 <result pre="became COVID-19 negative. Myopathic symptoms in a severe systemic viral" exact="disease" post="are multifactorial, but an acute onset of severe muscle"/>
 <result pre="in a severe systemic viral disease are multifactorial, but an" exact="acute" post="onset of severe muscle weakness with increased inflammatory markers"/>
 <result pre="viral disease are multifactorial, but an acute onset of severe" exact="muscle" post="weakness with increased inflammatory markers and very high CK"/>
 <result pre="levels in the thousands, as described above, is consistent with" exact="autoimmune" post="inflammatory myopathy within the spectrum of NAM, similar to"/>
 <result pre="the thousands, as described above, is consistent with autoimmune inflammatory" exact="myopathy" post="within the spectrum of NAM, similar to what was"/>
 <result pre="that epidemic.22,23 The most common causes of NAM are not" exact="chronic" post="statin use as overstated, but autoimmune, paraneoplastic, or postviral.22â€&quot;25"/>
 <result pre="or postviral.22â€&quot;25 Considering that very high CK level and painful" exact="muscle" post="weakness were seen in 10% of COVID-19â€&quot;positive patients,6 a"/>
 <result pre="were seen in 10% of COVID-19â€&quot;positive patients,6 a potentially treatable" exact="autoimmune" post="myopathy has been likely overlooked. Studies with muscle biopsy"/>
 <result pre="seen in 10% of COVID-19â€&quot;positive patients,6 a potentially treatable autoimmune" exact="myopathy" post="has been likely overlooked. Studies with muscle biopsy and"/>
 <result pre="potentially treatable autoimmune myopathy has been likely overlooked. Studies with" exact="muscle" post="biopsy and antibody screening are urgently needed in such"/>
 <result pre="facilitate recovery, as reported in the first 2 cases.20,21 COVID-19â€&quot;associated" exact="myositis" post="is also highly interesting because ACE-2, the SARS-CoV receptor,"/>
 <result pre="COVID-19 may represent the first virus directly capable of infecting" exact="muscle" post="fibers. None of the viruses implicated in viral-triggered myositis"/>
 <result pre="infecting muscle fibers. None of the viruses implicated in viral-triggered" exact="myositis" post="has so far been shown to infect muscle27,28; instead,"/>
 <result pre="infect muscle27,28; instead, viruses induce an immune T cell with" exact="clonal" post="expansion of viral-specific T cells or macrophage-mediated, muscle fiber"/>
 <result pre="cell with clonal expansion of viral-specific T cells or macrophage-mediated," exact="muscle" post="fiber autoinvasion with abundant proinflammatory cytokines.22,29,30 Other emerging postinfectious"/>
 <result pre="muscle fiber autoinvasion with abundant proinflammatory cytokines.22,29,30 Other emerging postinfectious" exact="autoimmune" post="neurologic disorders Acute disseminated encephalomyelitis, as described for the"/>
 <result pre="with abundant proinflammatory cytokines.22,29,30 Other emerging postinfectious autoimmune neurologic disorders" exact="Acute" post="disseminated encephalomyelitis, as described for the other coronaviruses, or"/>
 <result pre="brainstem encephalitis, myelitis, and radiculoneuropathies will not be unexpected. An" exact="atypical" post="case of acute necrotizing encephalopathy, attributed to immune-mediated process"/>
 <result pre="and radiculoneuropathies will not be unexpected. An atypical case of" exact="acute" post="necrotizing encephalopathy, attributed to immune-mediated process and proinflammatory cytokines,"/>
 <result pre="attributed to immune-mediated process and proinflammatory cytokines, and another with" exact="meningoencephalitis" post="and leptomeningeal enhancement have been already noted.31 This picture"/>
 <result pre="the Journal, documented by impressive MRIs; one, a case of" exact="acute" post="necrotizing brainstem encephalopathy, presented with epilepsy and changes in"/>
 <result pre="one, a case of acute necrotizing brainstem encephalopathy, presented with" exact="epilepsy" post="and changes in the right mesial temporal lobe and"/>
 <result pre="encephalopathy, presented with epilepsy and changes in the right mesial" exact="temporal lobe" post="and hippocampus32 and another with altered mental status and"/>
 <result pre="matter tumefactive lesions with postgadolinium enhancement in periventricular areas and" exact="corpus callosum" post="suggestive of demyelination.33 Not underestimating the overwhelming burden of"/>
 <result pre="callosum suggestive of demyelination.33 Not underestimating the overwhelming burden of" exact="acute" post="COVID-19 to medical staff, vigilance for these disorders is"/>
 <result pre="vigilance for these disorders is needed along with screening for" exact="autoimmune" post="encephalitis autoantibodies14 because these cases can potentially respond to"/>
 <result pre="for these disorders is needed along with screening for autoimmune" exact="encephalitis" post="autoantibodies14 because these cases can potentially respond to early"/>
 <result pre="gas or fire. Many discharged patients require assistance because of" exact="muscle" post="weakness and gait unsteadiness, which is arguably multifactorial; some"/>
 <result pre="is arguably multifactorial; some patients may have had critical illness" exact="neuropathy" post="and deconditioning with significant muscle atrophy worsened by comorbidities;"/>
 <result pre="may have had critical illness neuropathy and deconditioning with significant" exact="muscle" post="atrophy worsened by comorbidities; others may have neurotoxicity or"/>
 <result pre="have had critical illness neuropathy and deconditioning with significant muscle" exact="atrophy" post="worsened by comorbidities; others may have neurotoxicity or myocytotoxicity"/>
 <result pre="with significant muscle atrophy worsened by comorbidities; others may have" exact="neurotoxicity" post="or myocytotoxicity from antiviral therapies, like first described with"/>
 <result pre="described with antiretrovirals or chloroquine34â€&quot;36; still others may have the" exact="residual" post="effects from an unrecognized primary myopathy, neuropathy, or myelopathy"/>
 <result pre="still others may have the residual effects from an unrecognized" exact="primary" post="myopathy, neuropathy, or myelopathy due to postviral autoimmunity. A"/>
 <result pre="the residual effects from an unrecognized primary myopathy, neuropathy, or" exact="myelopathy" post="due to postviral autoimmunity. A study exploring the patients'"/>
 <result pre="postviral autoimmunity. A study exploring the patients' current causes of" exact="residual" post="muscle weakness and sensory deficits is urgently needed using"/>
 <result pre="autoimmunity. A study exploring the patients' current causes of residual" exact="muscle" post="weakness and sensory deficits is urgently needed using EMG,"/>
 <result pre="muscle weakness and sensory deficits is urgently needed using EMG," exact="muscle" post="or nerve biopsies, autoantibody screening, and CSF or imaging"/>
 <result pre="and sensory deficits is urgently needed using EMG, muscle or" exact="nerve" post="biopsies, autoantibody screening, and CSF or imaging studies to"/>
 <result pre="identify potential reversibility, and accelerate return to normalcy. Patients with" exact="autoimmune" post="neurologic diseases: how is COVID-19 changing ongoing immunotherapies and"/>
 <result pre="changing ongoing immunotherapies and the role of complement Patients with" exact="autoimmune" post="neuropathies, especially chronic inflammatory demyelinating polyneuropathy and multifocal motor"/>
 <result pre="and the role of complement Patients with autoimmune neuropathies, especially" exact="chronic" post="inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, but also"/>
 <result pre="role of complement Patients with autoimmune neuropathies, especially chronic inflammatory" exact="demyelinating" post="polyneuropathy and multifocal motor neuropathy, but also with other"/>
 <result pre="of complement Patients with autoimmune neuropathies, especially chronic inflammatory demyelinating" exact="polyneuropathy" post="and multifocal motor neuropathy, but also with other autoimmunities"/>
 <result pre="and multifocal motor neuropathy, but also with other autoimmunities like" exact="myasthenia gravis," post="MS, and inflammatory myopathies, have been justifiably concerned as"/>
 <result pre="inflammatory myopathies, have been justifiably concerned as to whether their" exact="disease" post="status adds an additional risk placing them into an"/>
 <result pre="There is no current evidence that any of the aforementioned" exact="autoimmune" post="disorder itself makes them more susceptible to COVID-19, but"/>
 <result pre="have this potential, although there are no validated data. Most" exact="autoimmune" post="neuromuscular patients are maintained on steroids, mycophenolate, or azathioprine"/>
 <result pre="patients are maintained on steroids, mycophenolate, or azathioprine while most" exact="chronic" post="inflammatory demyelinating polyneuropathy receive monthly IVIg. The same applies"/>
 <result pre="maintained on steroids, mycophenolate, or azathioprine while most chronic inflammatory" exact="demyelinating" post="polyneuropathy receive monthly IVIg. The same applies to patients"/>
 <result pre="on steroids, mycophenolate, or azathioprine while most chronic inflammatory demyelinating" exact="polyneuropathy" post="receive monthly IVIg. The same applies to patients with"/>
 <result pre="or continue treatment with the standard disease-modifying drugs. If clinically" exact="stable" post="and not lymphopenic, there are no compelling or data-driven"/>
 <result pre="immunity induced by disease-modifying drugs in patients with MS or" exact="neuromyelitis optica" post="spectrum disorder appears insufficient to enhance susceptibility to COVID-19"/>
 <result pre="MS or neuromyelitis optica spectrum disorder appears insufficient to enhance" exact="susceptibility to" post="COVID-19 infection. The results are important but not unexpected"/>
 <result pre="if any, effect on suppressing the innate immunity that facilitates" exact="infection" post="of macrophages and viral spread. Similar data from New"/>
 <result pre="suppressing the innate immunity that facilitates infection of macrophages and" exact="viral" post="spread. Similar data from New York City area show"/>
 <result pre="area show that the incidence of hospitalization among patients with" exact="immune-mediated inflammatory diseases" post="on therapy with steroids and biologic agents was consistent"/>
 <result pre="proinflammatory responses with evidence that activation of C3 exacerbates SARS-CoVâ€&quot;associated" exact="acute" post="respiratory distress syndrome and C3-C5 complement deposits are abundant"/>
 <result pre="responses with evidence that activation of C3 exacerbates SARS-CoVâ€&quot;associated acute" exact="respiratory" post="distress syndrome and C3-C5 complement deposits are abundant in"/>
 <result pre="evidence that activation of C3 exacerbates SARS-CoVâ€&quot;associated acute respiratory distress" exact="syndrome" post="and C3-C5 complement deposits are abundant in the lung"/>
 <result pre="that complement inhibition may alleviate the inflammatory complications of COVID-19" exact="infection" post="leading to ongoing trials with anti-C3 and anti-C5 agents.41,42"/>
 <result pre="On this basis, eculizumab, an anti-C5 monoclonal antibody approved for" exact="neuromyelitis optica" post="spectrum disorder and myasthenia gravis with some benefits in"/>
 <result pre="anti-C5 monoclonal antibody approved for neuromyelitis optica spectrum disorder and" exact="myasthenia gravis" post="with some benefits in patients with GBS, may not"/>
 <result pre="Neuroinflammation. Disclosures available: Neurology.org/NN. Glossary ACE-2 angiotensin-converting enzyme 2 AIDP" exact="acute" post="inflammatory demyelinating polyneuropathy AMAN acute motor axonal neuropathy CK"/>
 <result pre="available: Neurology.org/NN. Glossary ACE-2 angiotensin-converting enzyme 2 AIDP acute inflammatory" exact="demyelinating" post="polyneuropathy AMAN acute motor axonal neuropathy CK creatine kinase"/>
 <result pre="Neurology.org/NN. Glossary ACE-2 angiotensin-converting enzyme 2 AIDP acute inflammatory demyelinating" exact="polyneuropathy" post="AMAN acute motor axonal neuropathy CK creatine kinase CRP"/>
 <result pre="ACE-2 angiotensin-converting enzyme 2 AIDP acute inflammatory demyelinating polyneuropathy AMAN" exact="acute" post="motor axonal neuropathy CK creatine kinase CRP C-reactive protein"/>
 <result pre="enzyme 2 AIDP acute inflammatory demyelinating polyneuropathy AMAN acute motor" exact="axonal neuropathy" post="CK creatine kinase CRP C-reactive protein GBS Guillain-BarrÃ© syndrome"/>
 <result pre="2 AIDP acute inflammatory demyelinating polyneuropathy AMAN acute motor axonal" exact="neuropathy" post="CK creatine kinase CRP C-reactive protein GBS Guillain-BarrÃ© syndrome"/>
 <result pre="axonal neuropathy CK creatine kinase CRP C-reactive protein GBS Guillain-BarrÃ©" exact="syndrome" post="ICU intensive care unit IVIg intravenous immunoglobulin MERS Middle"/>
 <result pre="ICU intensive care unit IVIg intravenous immunoglobulin MERS Middle East" exact="respiratory" post="syndrome MFS Miller Fisher syndrome NAM necrotizing autoimmune myositis"/>
 <result pre="intensive care unit IVIg intravenous immunoglobulin MERS Middle East respiratory" exact="syndrome" post="MFS Miller Fisher syndrome NAM necrotizing autoimmune myositis References"/>
 <result pre="unit IVIg intravenous immunoglobulin MERS Middle East respiratory syndrome MFS" exact="Miller Fisher syndrome" post="NAM necrotizing autoimmune myositis References References 1.DalakasMCPathogenesis of immune-mediated"/>
 <result pre="IVIg intravenous immunoglobulin MERS Middle East respiratory syndrome MFS Miller" exact="Fisher syndrome" post="NAM necrotizing autoimmune myositis References References 1.DalakasMCPathogenesis of immune-mediated"/>
 <result pre="intravenous immunoglobulin MERS Middle East respiratory syndrome MFS Miller Fisher" exact="syndrome" post="NAM necrotizing autoimmune myositis References References 1.DalakasMCPathogenesis of immune-mediated"/>
 <result pre="Middle East respiratory syndrome MFS Miller Fisher syndrome NAM necrotizing" exact="autoimmune" post="myositis References References 1.DalakasMCPathogenesis of immune-mediated neuropathies Biochimica et."/>
 <result pre="East respiratory syndrome MFS Miller Fisher syndrome NAM necrotizing autoimmune" exact="myositis" post="References References 1.DalakasMCPathogenesis of immune-mediated neuropathies Biochimica et. Biophyiscal"/>
 <result pre="Biochimica et. Biophyiscal Acta2015;1852:658â€&quot;666. 2.WakerleyBR, YukiNInfectious and noninfectious triggers in" exact="Guillain-Barre syndrome." post="Expert Rev Clin Immunol2013;9:627â€&quot;639.23899233 3.Cao-LormeauVM, BlakeA, MonsS, et al.Guillain-Barre"/>
 <result pre="syndrome. Expert Rev Clin Immunol2013;9:627â€&quot;639.23899233 3.Cao-LormeauVM, BlakeA, MonsS, et al.Guillain-Barre" exact="syndrome" post="outbreak associated with Zika virus infection in French Polynesia:"/>
 <result pre="3.Cao-LormeauVM, BlakeA, MonsS, et al.Guillain-Barre syndrome outbreak associated with Zika" exact="virus infection" post="in French Polynesia: a case-control study. Lancet2016;387:1531â€&quot;1539.26948433 4.ZhuN, ZhangD,"/>
 <result pre="BlakeA, MonsS, et al.Guillain-Barre syndrome outbreak associated with Zika virus" exact="infection" post="in French Polynesia: a case-control study. Lancet2016;387:1531â€&quot;1539.26948433 4.ZhuN, ZhangD,"/>
 <result pre="4.ZhuN, ZhangD, WangW, et al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med2020;382:727â€&quot;733.31978945 5.GuanWJ, NiZY,"/>
 <result pre="J Med2020;382:727â€&quot;733.31978945 5.GuanWJ, NiZY, HuY, et al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med2020;382:1708â€&quot;1720.32109013 6.MaoL, JinH,WangM,"/>
 <result pre="6.MaoL, JinH,WangM, et al.Neurologic manifestations of hospitalized patients with coronavirus" exact="disease" post="2019 in Wuhan, China. JAMA Neurol202010.1001/jamaneurol.2020.1127. 7.ZhaoH, ShenD, ZhouH,"/>
 <result pre="in Wuhan, China. JAMA Neurol202010.1001/jamaneurol.2020.1127. 7.ZhaoH, ShenD, ZhouH, LiuJ, ChenSGuillain-BarrÃ©" exact="syndrome" post="associated with SARS-CoV-2 infection: causality or coincidence?Lancet Neurol2020;19:383â€&quot;384.32246917 8.ToscanoG,"/>
 <result pre="infection: causality or coincidence?Lancet Neurol2020;19:383â€&quot;384.32246917 8.ToscanoG, PalmeriniF, RavagliaS, et al.Guillainâ€&quot;BarrÃ©" exact="syndrome" post="associated with SARS-CoV-2. New Engl J Med202010.1056/NEJMc2009191. 9.AlbertiP, BerettaS,"/>
 <result pre="with SARS-CoV-2. New Engl J Med202010.1056/NEJMc2009191. 9.AlbertiP, BerettaS, PiattiMet al.Guillain-BarrÃ©" exact="syndrome" post="related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm2020;7:e741. doi: 10.1212/NXI.0000000000000741."/>
 <result pre="Neurol Neuroimmunol Neuroinflamm2020;7:e741. doi: 10.1212/NXI.0000000000000741. 10.GutiÃ©rrez-OrtizC, MÃ©ndezA, Rodrigo-ReyS, et al.Miller" exact="Fisher" post="Syndrome and polyneuritis cranialis in COVID-19. Neurology Epub 2020"/>
 <result pre="Neuroimmunol Neuroinflamm2020;7:e741. doi: 10.1212/NXI.0000000000000741. 10.GutiÃ©rrez-OrtizC, MÃ©ndezA, Rodrigo-ReyS, et al.Miller Fisher" exact="Syndrome" post="and polyneuritis cranialis in COVID-19. Neurology Epub 2020 Apr"/>
 <result pre="2020 Apr 17. doi: 10.1212/WNL.0000000000009619. 11.BigautK, MallaretM, BalogluS, et al.Guillain-BarrÃ©" exact="syndrome" post="related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm2020;7:e785. doi: 10.1212/NXI.0000000000000785.32461235"/>
 <result pre="doi: 10.1002/alr.22579. 13.DesforgesM, CoupanecA, DubeauP, et al.Human coronaviruses and other" exact="respiratory" post="viruses: underestimated opportunistic pathogens of the central nervous system."/>
 <result pre="coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the" exact="central nervous system." post="Viruses2019;12:14. 14.ArmangueT, SpatolaM, VlageaA, et al.Frequency, symptoms, risk factors,"/>
 <result pre="SpatolaM, VlageaA, et al.Frequency, symptoms, risk factors, and outcomes of" exact="autoimmune" post="encephalitis after herpes simplex encephalitis: a prospective observational study"/>
 <result pre="VlageaA, et al.Frequency, symptoms, risk factors, and outcomes of autoimmune" exact="encephalitis" post="after herpes simplex encephalitis: a prospective observational study and"/>
 <result pre="al.Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after" exact="herpes" post="simplex encephalitis: a prospective observational study and retrospective analysis."/>
 <result pre="glycolipids the responsible autoantigens?Ann Neurol1996;39:419â€&quot;422.8619518 18.KusunokiS, ShimizuJ, ChibaA, et al.Experimental" exact="sensory neuropathy" post="induced by sensitization with ganglioside GD1b. Ann Neurol1996;39:424â€&quot;431.8619520 19.DauneGC,"/>
 <result pre="the responsible autoantigens?Ann Neurol1996;39:419â€&quot;422.8619518 18.KusunokiS, ShimizuJ, ChibaA, et al.Experimental sensory" exact="neuropathy" post="induced by sensitization with ganglioside GD1b. Ann Neurol1996;39:424â€&quot;431.8619520 19.DauneGC,"/>
 <result pre="sensitization with ganglioside GD1b. Ann Neurol1996;39:424â€&quot;431.8619520 19.DauneGC, FarrerRG, DalakasMC, QuarlesRHSensory" exact="neuropathy" post="associated with monoclonal IgM to GD1b ganglioside. Ann Neurol1992;31:683â€&quot;685.1381168"/>
 <result pre="associated with 2019 novel coronavirus disease. Emerg Infect Dis2020;26. 22.DalakasMCInflammatory" exact="muscle" post="diseases. N Engl J Med2015;372:1734â€&quot;1747.25923553 23.DalakasMC, PezeshkpourGH, GravellM, SeverJLPolymyositis"/>
 <result pre="27.LeffRL, LoveLA, MillerFW, et al.Viruses in the idiopathic inflammatory myopathies:" exact="absence of" post="candidate viral genomes in muscle. Lancet1992;339:1192â€&quot;1195.1349938 28.Leon-MonzonM, LamperthL, DalakasMCSearch"/>
 <result pre="et al.Viruses in the idiopathic inflammatory myopathies: absence of candidate" exact="viral" post="genomes in muscle. Lancet1992;339:1192â€&quot;1195.1349938 28.Leon-MonzonM, LamperthL, DalakasMCSearch for HIV"/>
 <result pre="DalakasMCSearch for HIV proviral DNA and amplified sequences in the" exact="muscle" post="biopsies of patients with HIV polymyositis. Muscle Nerve1993;16:408â€&quot;413.8455655 29.IllaI,"/>
 <result pre="sequences in the muscle biopsies of patients with HIV polymyositis." exact="Muscle" post="Nerve1993;16:408â€&quot;413.8455655 29.IllaI, NathA, DalakasMCImmunocytochemical and virological characteristics of HIV-associated"/>
 <result pre="seronegative polymyositis. Ann Neurol1991;29:474â€&quot;481.1859178 30.DalakasMC, RakocevicG, ShatunovA, et al.Inclusion body" exact="myositis" post="with human immunodeficiency virus infection: four cases with clonal"/>
 <result pre="Neurol1991;29:474â€&quot;481.1859178 30.DalakasMC, RakocevicG, ShatunovA, et al.Inclusion body myositis with human" exact="immunodeficiency" post="virus infection: four cases with clonal expansion of viral-specific"/>
 <result pre="body myositis with human immunodeficiency virus infection: four cases with" exact="clonal" post="expansion of viral-specific T cells. Ann Neurol2007;61:466â€&quot;475.17366634 31.MoriguchiT, HariiN,"/>
 <result pre="SARS-Coronavirus-2. Int J Infect Dis2020;94:55â€&quot;58.32251791 32.DixonL, VarleyJ, GontsarovaA, et al.COVID-19-related" exact="acute" post="necrotizing encephalopathy with brain stem involvement in a patient"/>
 <result pre="J Infect Dis2020;94:55â€&quot;58.32251791 32.DixonL, VarleyJ, GontsarovaA, et al.COVID-19-related acute necrotizing" exact="encephalopathy" post="with brain stem involvement in a patient with aplastic"/>
 <result pre="Dis2020;94:55â€&quot;58.32251791 32.DixonL, VarleyJ, GontsarovaA, et al.COVID-19-related acute necrotizing encephalopathy with" exact="brain" post="stem involvement in a patient with aplastic anemia. Neurol"/>
 <result pre="necrotizing encephalopathy with brain stem involvement in a patient with" exact="aplastic anemia." post="Neurol Neuroimmunol Neuroinflamm2020;7:e789. doi: 10.1212/NXI.0000000000000789.32457227 33.BrunG, HakJF, CozeS, et"/>
 <result pre="Neuroimmunol Neuroinflamm2020;7:e777. doi: 10.1212/NXI.0000000000000777.32444427 34.DalakasMC, IllaI, PezeshkpourGH, LaukaitisJP, CohenB, GriffinJMitochondrial" exact="myopathy" post="caused by long-term zidovudine therapy. N Engl J Med1990;332:1098â€&quot;1105."/>
 <result pre="caused by long-term zidovudine therapy. N Engl J Med1990;332:1098â€&quot;1105. 35.DalakasMCPeripheral" exact="neuropathy" post="and antiretroviral drugs. J Peripher Nerv Syst2001;6:14â€&quot;20.11293802 36.SteinM, BellMJ,"/>
 <result pre="the PATH Study Group. Subcutaneous immunoglobulin for maintenance treatment in" exact="chronic" post="inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase"/>
 <result pre="Study Group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory" exact="demyelinating" post="polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial."/>
 <result pre="Group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating" exact="polyneuropathy" post="(PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet"/>
 <result pre="for neurology. Neurology2008;70:2252â€&quot;2260.18519875 39.FanM, QiuW, BuB, et al.Risk of COVID-19" exact="infection" post="in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol"/>
 <result pre="QiuW, BuB, et al.Risk of COVID-19 infection in MS and" exact="neuromyelitis optica" post="spectrum disorders. Neurol Neuroimmunol Neuroinflamm2020;7:e787. doi: 10.1212/NXI.0000000000000787.32503092 40.HabernanR, AxelradJ,"/>
</results>
